Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | MAPK7 | Q13164 | 11/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14814930 | 0.84 | JAK2 (0.39) | MGLLMAPK7SCN9ASCN10AEPHX2 | |
| SCHEMBL14815202 | 0.81 | JAK2 (0.36) | EGLN1HRH3HSD11B1 | |
| SCHEMBL14815458 | 0.81 | GAA (0.41) | MGLLMAPK7EGLN1HSD11B1 | |
| SCHEMBL14815222 | 0.80 | P2RX7 (0.39) | MGLLMAPK7SCN9AHRH3HSD11B1 | |
| SCHEMBL14815225 | 0.79 | RBP4 (0.44) | MGLLHSD11B1 | |
| SCHEMBL14815341 | 0.79 | HRH3 (0.43) | MAPK7SCN9ASCN10AEPHX2EGLN1 | |
| SCHEMBL14815371 | 0.79 | RBP4 (0.44) | MGLLHSD11B1 | |
| SCHEMBL14815054 | 0.79 | MGLL (0.39) | MGLLMAPK7SCN9ASCN10AEPHX2 | |
| SCHEMBL14815378 | 0.78 | KMT2A (0.42) | MGLLSCN9ASCN10A | |
| SCHEMBL14815342 | 0.78 | KDM4E (0.38) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | MGLL 4703/4885MAPK7 3250/4885SCN9A 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.